Hexarelin has been well tolerated in clinical studies. Common side effects include flushing and mild cortisol/prolactin elevation. Unlike ipamorelin, it is not selective for GH only. Long-term safety data is limited. Clinical supervision is strongly recommended.

Why does the GH response decrease over time?

Hexarelin causes tachyphylaxis. The ghrelin receptors (GHS-R1a) internalize and downregulate with repeated stimulation. This reduces receptor availability and diminishes the GH response within weeks of continuous use. This is more rapid with hexarelin than with less potent GHRPs.

How does hexarelin protect the heart?

Hexarelin activates CD36 receptors on cardiac muscle cells, which appears to mediate direct cardioprotective effects independent of growth hormone release. Human studies have shown improvements in left ventricular ejection fraction and cardiac output through this mechanism.

Is hexarelin FDA approved?

No. Hexarelin is not FDA-approved for any indication. It remains on the FDA Category 2 restricted compounding list, meaning licensed compounding pharmacies cannot legally prepare it.

How does hexarelin compare to ipamorelin?

Hexarelin is more potent for acute GH release but less selective. It elevates cortisol and prolactin while ipamorelin does not. Hexarelin develops tachyphylaxis more rapidly. Ipamorelin is considered more practical for sustained use due to its cleaner hormonal profile and resistance to desensitization.

What does the research show about: The most potent GHRP for acute GH release in humans, producing larger GH pulses ?

The most potent GHRP for acute GH release in humans, producing larger GH pulses than GHRP-2, GHRP-6, or ipamorelin. Potency is the defining pharmacological feature, but potency alone does not equal clinical utility due to tachyphylaxis

What does the research show about: Direct cardiac protective effects mediated through CD36 receptors, independent o?

Direct cardiac protective effects mediated through CD36 receptors, independent of GH secretion. Human studies confirm improved left ventricular ejection fraction and cardiac output. This dual mechanism distinguishes hexarelin from other GHRPs

What does the research show about: Tachyphylaxis (diminishing GH response) occurs within weeks of continuous use du?

Tachyphylaxis (diminishing GH response) occurs within weeks of continuous use due to GHS-R1a internalization. This is the primary practical limitation. The strong initial GH response does not predict sustained elevation with continued use

What does the research show about: Non-selective hormonal profile: elevates cortisol and prolactin alongside GH, un?

Non-selective hormonal profile: elevates cortisol and prolactin alongside GH, unlike ipamorelin. The non-selective profile combined with tachyphylaxis has limited clinical development interest compared to more selective alternatives

What does the research show about: Approximately 20 human studies provide a moderate evidence base across GH pharma?

Approximately 20 human studies provide a moderate evidence base across GH pharmacokinetics and cardiac effects. More human data than most GH secretagogues, though no large-scale clinical outcome trials exist

reviewed april 2026|next review october 2026|88 physicians psi has verified|311 published studies

Hexarelin

Hexarelin is a synthetic hexapeptide growth hormone secretagogue with the strongest GH-releasing potency documented in human studies and a unique secondary mechanism of cardiac protection through the CD36 scavenger receptor.

Evidence landscape: 311 published studies

311 published items. 30 human studies and 146 animal studies. The deepest human evidence base of any non-approved GH secretagogue.

30 Human
146 Animal
24 Reviews
111 Other research

The strongest growth hormone pulse documented in human studies among all synthetic GH secretagogues.

Activates the CD36 scavenger receptor on cardiac muscle cells, producing cardioprotective effects independent of growth hormone release. No other GHRP shares this mechanism.

The GH response diminishes within weeks of continuous use due to receptor internalization, faster than with any other GHRP.

PSI Assessment

The most potent growth hormone secretagogue ever tested in humans also does something no other GHRP does: it directly protects cardiac muscle through a receptor (CD36) that has nothing to do with growth hormone. That dual mechanism makes hexarelin scientifically unique in the GH secretagogue class. The practical limitation is equally distinctive: tachyphylaxis causes the GH response to diminish within weeks of continuous use, faster than with any other GHRP.

The strongest GH-releasing potency of any secretagogue tested in humans. Unique cardiac protection through CD36. The GH response diminishes within weeks.

The mechanism has two arms. The growth hormone arm operates through ghrelin receptor (GHS-R1a) agonism, triggering the strongest GH pulse of any synthetic GHRP tested in humans. But hexarelin also activates the CD36 scavenger receptor on cardiac myocytes, producing anti-apoptotic and anti-fibrotic effects that are independent of GH release. The non-selective hormonal profile (cortisol and prolactin elevation alongside GH) and rapid tachyphylaxis from receptor internalization are the practical limitations.

What the evidence supports

Hexarelin produces the strongest GH-releasing response of any synthetic secretagogue tested in humans. The CD36-mediated cardiac protection is documented in both animal models and human studies, operating independently of GH release. Non-selective hormonal profile (cortisol and prolactin elevation) is well-characterized. 30 human studies provide the deepest evidence base of any non-approved GH secretagogue.

What is not yet established

Whether the cardiac protective effects translate to clinical cardiovascular outcomes. Long-term safety with the non-selective hormonal profile. How to manage the rapid tachyphylaxis that limits sustained GH elevation. Whether the CD36 mechanism can be therapeutically exploited without the GH axis effects.

Research Evidence

The findings below cover the GH potency data, the unique CD36 cardiac mechanism, and the tachyphylaxis limitation that defines the practical profile.

Evidence by condition

Evidence dimensions across hexarelin's investigated conditions. GH stimulation and cardiac protection have the deepest evidence.

Condition	Mechanism	Animal evidence	Human evidence	Replication
GH Stimulation
Cardiac Protection
Body Composition
Bone Health

Hexarelin produces the strongest GH pulse documented in human studies among all synthetic GH secretagogues. The response is dose-dependent, peaks within 15-30 minutes, and is reproducible across multiple studies. The non-selective profile also elevates cortisol and prolactin alongside GH.

The potency distinction is well-established across comparative human pharmacology studies. The non-selective hormonal profile is the trade-off for that potency.

Hexarelin activates the CD36 scavenger receptor on cardiac myocytes, producing anti-apoptotic and anti-fibrotic effects that are independent of growth hormone release. Human studies in heart failure patients demonstrate improved left ventricular ejection fraction and cardiac output through this GH-independent pathway.

The CD36 cardiac mechanism is unique to hexarelin among all GHRPs. No other synthetic GH secretagogue has documented this dual-receptor action.

Tachyphylaxis occurs within weeks of continuous use due to GHS-R1a receptor internalization and downregulation. The GH response diminishes faster with hexarelin than with less potent GHRPs, likely because the stronger agonism drives faster receptor internalization.

The rapid tachyphylaxis is the primary practical limitation. It restricts the duration of sustained GH elevation achievable with continuous dosing.

30 Human|146 Animal|24 Reviews

View all 311 indexed studies

How Hexarelin Works

Hexarelin is a synthetic hexapeptide that binds two distinct receptors: the ghrelin receptor (GHS-R1a) for GH release and the CD36 scavenger receptor on cardiac tissue for cardioprotection.

Hexarelin does two things most GH peptides don't. It raises growth hormone powerfully AND appears to directly protect heart muscle cells through a separate receptor. This dual action is what makes it scientifically interesting beyond just being a GH secretagogue.

For a more detailed view of the biology, here is what researchers have observed at the molecular level.

Hexarelin stimulates GH release by binding GHS-R1a with high affinity, producing the strongest GH pulse of any synthetic GHRP. It also interacts with CD36 on cardiomyocytes and macrophages, mediating direct cardioprotective effects independent of GH. The non-selective hormonal profile includes CRH activation (elevating cortisol) and dopamine pathway modulation (elevating prolactin). Tachyphylaxis occurs through GHS-R1a internalization and downregulation.

What is Hexarelin being studied for?

Researchers are studying Hexarelin across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for Hexarelin overall. This means a compound can have human studies for one condition but only animal data for another.

GH Stimulation

·Human Trials

Hexarelin produces the strongest GH pulse documented in human studies among all synthetic GH secretagogues. The response is dose-dependent and reproducible. Tachyphylaxis within weeks of continuous use is the primary practical limitation.

Limitations: GH response diminishes significantly within weeks of continuous dosing due to GHS-R1a receptor internalization. No clinical outcomes data exists for sustained use.

Cardiac Protection

·Human Trials

Human studies show hexarelin improves left ventricular ejection fraction and cardiac output independent of GH release, mediated through CD36 receptor activation on cardiac myocytes.

Limitations: Cardiac studies are small and exploratory. Whether effects persist with chronic use is unknown. No large-scale cardiac outcomes trials have been conducted.

Body Composition

·Animal Studies

GH elevation from hexarelin theoretically improves body composition, but the rapid tachyphylaxis limits sustained GH elevation needed for meaningful body composition changes.

Limitations: The tachyphylaxis issue means sustained GH elevation is not achievable with continuous dosing. Limited human body composition data exists specifically for hexarelin.

Bone Health

·Animal Studies

Human studies show hexarelin influences bone turnover markers, consistent with the known effects of GH/IGF-1 on bone metabolism.

Limitations: Bone density outcomes have not been evaluated. The tachyphylaxis issue limits the duration of GH elevation needed to meaningfully affect bone remodeling.

Safety and Regulatory Status

FDA Status: Not FDA-approved for any indication.

Availability: On the FDA Category 2 list, meaning licensed pharmacies cannot currently compound it - the compound is restricted from preparation by compounding pharmacies.

WADA Status: Classified as a prohibited substance by the World Anti-Doping Agency.

Flushing is the most commonly reported side effect. Hexarelin elevates cortisol and prolactin alongside GH, unlike more selective alternatives like ipamorelin. The non-selective hormonal profile is the primary safety consideration with sustained use.

Peptide Structure

Technical molecular data for researchers and clinicians.

Questions and Comparisons

Questions the evidence raises for a Hexarelin discussion.

Comparison and Related Research

Hexarelin is most often compared with ipamorelin (selective, no cardiac effects), GHRP-6 (less potent, different secondary research), and GHRP-2 (Japan-approved diagnostic use).

Head-to-head comparisons

Full research comparisons covering Hexarelin and another peptide side by side.

Hexarelin vs GHRP-6

Both produce strong GH release but with different side effects. Hexarelin has cardiac research. GHRP-6 has more hunger. Evidence-graded comparison.

View full comparison

Related compounds

Ipamorelin GHRP-6 GHRP-2 CJC-1295

Frequently Asked Questions

References

Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.

1.Early clinical study testing multiple routes of hexarelin administration in healthy volunteers. Intravenous and subcutaneous delivery produced strong GH release, while intranasal and oral routes showed reduced but measurable activity.Ghigo E et al., 1994 in J Clin Endocrinol Metab. View on PubMed
2.Clinical study examining the cardiac effects of hexarelin in patients undergoing coronary bypass surgery. Acute administration improved several measures of heart function, suggesting a direct cardiovascular benefit independent of GH release.Broglio F et al., 2002 in Eur J Pharmacol. View on PubMed
3.Dose-response study in human subjects across age groups measuring hormonal responses to hexarelin. GH release declined with age while prolactin and cortisol responses remained relatively stable, indicating age-dependent receptor sensitivity changes.Arvat E et al., 1997 in Eur J Endocrinol. View on PubMed
4.Identified and characterized receptors for hexarelin and ghrelin in cardiac tissue and breast cancer cell lines. The study demonstrated that hexarelin binds to a specific cardiac receptor (later identified as CD36), providing evidence for a direct pathway through which growth hormone secretagogues may affect heart tissue.Cassoni P et al., 2001 in J Clin Endocrinol Metab. View on PubMed

Medical Disclaimer

This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.